Comparing Myostatin vs Activin A Inhibition to Understand Metabolic Trade-Offs for Obesity Combinations
- Comparing preclinical data on myostatin-only vs. dual myostatin/activin A inhibitors to increased understanding of differentiating factors
- Guiding pharmaceutical partnerships and clinical trial designs for combination optimisation
- Identifying outcomes for patient subset identification in clinical stages